ChemotherapyFDA-approvedFirst-line
Carboplatin + Paclitaxel
How it works
Carboplatin damages DNA in cancer cells, while paclitaxel prevents cell division, leading to cell death.
Cancer types
Lung Cancer— All patients
Efficacy
In clinical trials, around 30% of patients achieved an objective response, with a median overall survival of approximately 9.4 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.